Introduction {#Sec1}
============

Pyrimidine is the six membered heterocyclic organic colorless compound containing two nitrogen atoms at 1st and 3rd positions (Fig. [1](#Fig1){ref-type="fig"}). The name of the pyrimidine was first applied by Pinner from the combination of two words pyridine and amidine). Pyrimidines(1,3-diazines) and their fused analogues form a large group of heterocyclic compounds. Pyrimidine which is an integral part of DNA and RNA imparts diverse pharmacological properties. The pyrimidine have been isolated from the nucleic acid hydrolyses and much weaker base than pyridine and soluble in water \[[@CR1]\]. Pyrimidine and its derivatives have been described with a wide range of biological potential i.e. anticancer \[[@CR2]\], antiviral \[[@CR3]\], antimicrobial \[[@CR4]\], anti-inflammatory \[[@CR5]\], analgesic \[[@CR6]\], antioxidant \[[@CR7]\] and antimalarial \[[@CR8]\] etc.Fig. 1Pyrimidine ring

Biological significance of pyrimidine scaffolds {#Sec2}
===============================================

Antimicrobial activity {#Sec3}
----------------------

The growing health problems demands for a search and synthesis of a new class of antimicrobial molecules which are effective against pathogenic microorganisms. Despite advances in antibacterial and antifungal therapies, many problems remain to be solved for most antimicrobial drugs available. The extensive use of antibiotics has led to the appearance of multidrug resistant microbial pathogens which necessitated the search for new chemical entities for treatment of microbial infections \[[@CR9]\].

Anupama et al. synthesized a series of 2,4,6-trisubstituted pyrimidines by reacting chalcone with guanidine hydrochloride. All the synthesized derivatives were confirmed by physicochemical properties and spectral data (IR, NMR and elemental analyses) and screened their in vitro antimicrobial activity against bacterial and fungal strains by cup plate method using Mueller--Hinton agar medium. Among the derivatives tested, compounds, **a1**, **a2** and **a3** exhibited promising activity against microbial strains (*B. pumilis, B. subtilis, E. coli, P. vulgaris. A. niger* and *P. crysogenium*) and showed activity comparable with standard drugs. Structure activity relationship (SAR) studies indicated that compounds, **a1**, **a2** and **a3** having dimethylamino, dichlorophenyl and fluorine substituent on the phenyl ring at 4th position respectively exhibited better antimicrobial activity (Table [1](#Tab1){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR4]\].Table 1Antimicrobial activity of compounds **(a1**--**a3)**CompoundsZone of inhibition (in mm)Microbial species*B. subtilisB. pumilisE. coliP. vulgarisA. nigerP. crysogenium***a1** A151211121112 B201420181314**a2** A161312151615 B201521211818**a3** A171413141514 B201521201717C------------S A252926282324 B303129312827A: 0.05 ml (50 μg); B: 0.1 ml (100 μg); C: control (DMSO); S: standard (benzyl penicillin for bacterial strains) and fluconazole for fungal strains Fig. 2Chemical structure of the most active antimicrobial pyrimidine derivatives (**a1**--**a12**)

Chen et al. synthesized a novel series of 4-substituted-2-{\[(1*H*-benzo\[*d*\]imidazol-2-yl) methyl\]thio}-6-methylpyrimidines from pyrimidine--benzimidazole combination. All the synthesized derivatives were fully characterized by ^1^H-NMR, ^13^C-NMR and HRMS study and screened its in vitro antimicrobial activity against Gram-positive bacteria (*Staphylococcus aureus, Bacillus subtilis*), Gram-negative bacteria (*Escherichia coli, Stenotrophomonas maltophilia*) and fungi (*Candida albicans*). The minimum inhibitory concentration (MIC) of the target compounds was determined by broth microdilution method and compared to two commercial antibiotics (levofloxacin and fluconazole). Among the entire synthesized derivatives, compounds, **a4** and **a5** were found to be the most active antimicrobial agents (Table [2](#Tab2){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). Structure activity relationship showed that aromatic amines at pyrimidine ring are beneficial for the antimicrobial activity. Besides, the aniline containing *para*-substituted groups (especially Cl and Br) is more beneficial for the activity \[[@CR10]\].Table 2Antimicrobial activity (MIC = µg/ml) of compounds **a4** and **a5**CompoundsBacterial strainsFungal strain*Staphylococcus aureusBacillus subtilisEscherichia coliStenotrophomonas maltophiliaCandida albicans***a4**8128128264**a5**1612812848Levofloxacin0.50.250.1250.25--Fluconazole--------2

El-Gaby et al. developed a new class of pyrrolo\[2,3-*d*\]pyrimidines containing sulfonamide moieties and screened its in vitro antifungal activity against four species of fungi viz: *Aspergillus ochraceus* (Wilhelm), *Penicillium chrysogenum* (Thom), *Aspergillus fleavus* (Link) and *Candida albicans* (Robin) Berkho by disc diffusion technique. Most of the synthesized molecules in this series were found to possess antifungal activity (Table [3](#Tab3){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) towards all the microorganisms' used especially, compound **a6** exhibited a remarkable antifungal activity which is comparable to the standard fungicide drug mycostatin \[[@CR11]\].Table 3Antifungal activity of synthesized compound **a6**CompoundZone of inhibition (mm)Fungal species*A*. *ochraceus* (AUCC-230)*P*. *chrysogenum* (AUCC-530)*A*. *flea*v*us* (AUCC-164)*C*. *albicans* (AUCC-1720)**a6**18 (45%)14 (37%)16 (42%)34 (85%)Mycostatine40 (100)38 (100%)38 (100%)40 (100%)

Hilmy et al. developed a new series of pyrrolo\[2,3-*d*\]pyrimidine derivatives. The synthesized compounds were confirmed by IR, NMR, Mass and elemental analysis study and evaluated its antimicrobial activity against bacterial (*Staphylococcus aureus*, *Escherichia coli*) and fungal (*Candida albicans*) organisms was carried out by serial dilution method. All synthesized derivatives showed that good antimicrobial activity, especially, compounds, **a7**, **a8**, **a9** were exhibited the better antimicrobial activity and compared with the standard drug (ampicillin and fluconazole) (Table [4](#Tab4){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR12]\].Table 4The MIC (mg/ml) value of the compounds **a7**, **a8** and **a9** tested against organismsCompoundsAntimicrobial results (MIC = mg/ml)*Escherichia coliStaphylococcus aureusCandida albicans***a7**1.250.310.31**a8**1.250.310.62**a9**1.250.310.31Ampicillin1.250.62--Fluconazole----1.5

Holla et al. developed a new class of pyrazolo\[3,4-*d*\]pyrimidine derivatives. The synthesized derivatives were analyzed for N content and their structures were confirmed by IR, NMR and Mass spectral data and screened their antibacterial activity against *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Bacillus subtilis* by disk diffusion method and antifungal activity against *Aspergillus flavus*, *Aspergillus fumigates, Candida albicans*, *Penicillium marneffei* and *Trichophyton mentagrophytes* by serial plate dilution method. All synthesized pyrazolo\[3,4-*d*\]pyrimidine derivatives in this series showed that good antimicrobial and fungal activity against bacterial and fungal strains, especially compounds, **a10** displayed very good antibacterial activity (Table [5](#Tab5){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) and **a11** exhibited antifungal activity (Table [6](#Tab6){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR13]\].Table 5Antibacterial activity data of compound **a10**CompoundZone of inhibition (mm) of bacterial species*Escherichia coliStaphylococcus aureusPseudomonas aeruginosaBacillus subtilis* (recultured)**a10**28252426Streptomycin20212424 Table 6Antifungal activity data of prepared compound **a11**CompoundZone of inhibition (mm) of fungal species*Aspergillus flavusAspergillus fumigatusTrichophyton mentagrophytes* (recultured)**a11**252224Fluconazole211819

Mallikarjunaswamy et al. synthesized a series of novel 2-(5-bromo-2-chloro-pyrimidin-4-ylsulfanyl)-4-methoxy-phenylamine derivatives by the reaction of 2-(5-bromo-2-chloro-pyrimidin-4-ylsulfanyl)-4-methoxy-phenylamine with various sulfonyl chlorides and its molecular structures were characterized by elemental analyses, FT-IR, ^1^H-NMR and LC--MS spectral studies and screened in vitro antimicrobial activity against Gram-positive bacteria (*Bacillus subtilis*, *Staphylococcus aureus*) and Gram-negative bacteria (*Xanthomonas campestris* and *Escherichia coli*) in dimethylformamide by disc diffusion method on nutrient agar medium and antifungal activity against *Fusarium oxysporum* in dimethylformamide by poisoned food technique. Among them, compound **a12** was found to be most potent against fungal strain (*Fusarium oxysporum*) and bacterial strains (*Bacillus subtilis*, *Staphylococcus aureus*, *Xanthomonas campestris* and *Escherichia coli*) and compared with standard antimicrobial drugs (Table [7](#Tab7){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR9]\].Table 7In vitro antibacterial and antifungal activities of compound **a12**CompoundZone of inhibition in diameter (mm) % inhibitionMicrobial species*B. subtilisS. aureusX. campestrisE. coliF. oxysporum***a12**3329323396.9Bacteriomycin----34----Gentamycin3530--35--Nystatin100

A new series of 1,2,4-triazolo\[1,5-*a*\]pyrimidine derivatives bearing 1,3,4-oxadiazole moieties was designed and synthesized by Chen et al. The molecular structures of all new compounds were characterized by spectral means (^1^H-NMR, Mass and elemental analyses) and evaluated their in vitro antifungal activity against *Rhizoctonia solani*. In this series, compounds, **a13** and **a14** displayed the highest antifungal activity against *Rhizoctonia solani* with EC~50~ = 3.34 µg/ml and EC~50~ = 6.57 µg/ml values respectively than the carbendazim (EC~50~ = 7.62 µg/ml) due to presence of the *sec*-butyl group (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR14]\].Fig. 3Chemical structure of the most active antimicrobial pyrimidine derivatives (**a13**--**a21**)

A new library of 5-amino-6-(benzo\[*d*\]thiazol-2-yl)-2-(2-(substituted benzylidene) hydrazinyl)-7-(4-chlorophenyl)pyrido\[2,3-*d*\]pyrimidin-4(3*H*)-one derivatives was synthesized by Maddila et al. and evaluated its antibacterial activity against *Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa* and *Streptococcus pyogenes* and antifungal activity against *Aspergillus flavus, Aspergillus fumigatus, Candida albicans, Penicillium marneffei* and *Mucor* by the twofold serial dilution method. Compounds, **a15**, **a16** and **a17** showed excellent antibacterial and antifungal activity than the standard drugs ciprofloxacin and clotrimazole respectively (Tables [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}) \[[@CR15]\].Table 8Antibacterial activity results of compounds **(a15**--**a17)**CompoundsMinimum inhibitory concentration (MIC = µg/ml)Bacterial species*S. aureusE. coliK. pneumoniaeP. aeruginosaS. pyogenes***a15**12.525252512.5**a16**12.512.512.512.512.5**a17**2512.512.52512.5Ciprofloxacin2525502512.5 Table 9Antifungal activity results of compounds **(a15**--**a17)**CompoundsMinimum inhibitory concentration (MIC = µg/ml)Fungal species*A. flavusA. fumigatusC. albicansP. marneffeiMucor***a15**12.512.5252512.5**a16**12.512.512.512.512.5**a17**2512.52512.525Clotrimazole2525502550

Fellahil et al. synthesized a new series of 5-(1,2-diarylethyl)-2,4,6-trichloro pyrimidines and 2-amino- and 2-(1-piperazinyl)-5-(1,2-diarylethyl)-4,6-dichloro pyrimidines via organozinc reagents and demonstrated its antibacterial activity against human bacterial flora. Biological tests showed that 5-\[1-(4-chlorophenyl)-2-phenylethyl\]-2,4,6-trichloro pyrimidine derivatives i.e. compounds **a18** and **a19** were found to be most active against wide range of bacterial flora of the axilla and foot, while 2-(1-piperazinyl)-4,6-dichloro pyrimidine derivatives **a20** and **a21** displayed a great selectivity against *Corynebacterium xerosis* and *Arcanobacterium haemolyticum* of the human axilla (Table [10](#Tab10){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}) \[[@CR16]\].Table 10Pharmacological evaluation (MIC = µg/ml) of the 2-substituted 5-(1,2-diarylethyl)-4,6-dichloropyrimidines**a18a19a20a21**Axillary bacterial flora *Staphylococcus xylosus*20100100100 *Staphylococcus epidermidis*10010010075 *Staphylococcus haemolyticus*10010010050 *Corynebacterium xerosis*20303030 *Micrococcus luteus*20100100100 *Arcanobacterium haemolyticum*10101010Foot bacterial flora *Staphylococcus epidermidis*\> 10010010075 *Staphylococcus hominis*10010010075 *Staphylococcus cohnii*10010010075 *Corynebacterium* sp. g C10010010075 *Corynebacterium* sp. g B3010010050 *Corynebacterium* sp. g D2301005050 *Micrococcus luteus*2010010075 *Micrococcus sedentarius*3010010075 *Acinetobacter* sp.\> 1000\> 5005030 *Moraxella* sp.3003010050 *Alcaligenes* sp.1000\> 500\> 500\> 500

Nagender et al. developed a new series of novel pyrazolo\[3,4-*b*\]pyridine and pyrimidine functionalized 1,2,3-triazole derivatives using 6-trifluoro methylpyridine-2(1*H*) one and screened its antimicrobial activity against i.e. *Micrococcus luteus* MTCC 2470, *Staphylococcus aureus* MTCC 96, *Staphylococcus aureus* MLS-16 MTCC 2940, *Bacillus subtilis* MTCC 121, *Escherichia coli* MTCC 739, *Pseudomonas aeruginosa* MTCC 2453, *Klebsiella planticola* MTCC 530 and *Candida albicans* MTCC 3017. In this series, compounds, **a22**, **a23** and **a24** were displayed better antimicrobial activity but less than the standard drugs (ciprofloxacin) (Table [11](#Tab11){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR17]\].Table 11MIC values of the compounds **a22, a23** and **a24**CompoundsMinimum inhibitory concentration (µg/ml)*M. luteusS. aureusS. aureusB. subtilisE. coliP. aeruginosaK. planticola***a22**7.815.615.615.67.87.815.6**a23**\> 25015.67.815.615.615.67.8**a24**15.67.87.815.67.87.87.8Ciprofloxacin0.90.90.90.90.90.90.9 Fig. 4Chemical structure of the most active antimicrobial pyrimidine derivatives (**a22**--**a30**)

Patel et al. synthesized a new series of pyrimidine derivatives and demonstrated its antimicrobial activity (Minimum inhibitory concentration) against four different strains, viz two Gram positive bacteria (*S. aureus* and *S. pyogenes*) and two Gram negative bacteria and (*E. coli* and *P. aeruginosa*) compared it with standard drugs ampicillin, chloramphenicol, ciprofloxacin and norfloxacin and antifungal activities against *C. albicans* and *A. niger* using nystatin as standard drug by broth dilution method, compounds, **a25** and **a26** were showed promising antimicrobial activity (Table [12](#Tab12){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR18]\].Table 12Antimicrobial activity of compounds **a25** and **a26**CompoundsMicrobial strains (µg/ml)*E. coliP. aeruginosaS. aureusS. pyogenusC. albicansA. niger***a25**62.5200100100200250**a26**255010050500250Chloramphenicol50505050----Ciprofloxacin25255050----Norfloxacin10101010----Nystatin100100

A new library of pyrazolo\[3,4-*d*\]pyrimidine derivatives was synthesized by Rostamizadeh et al. and screened for its antibacterial activity against two Gram-negative strains of bacteria: *Pseudomonas aeruginosa* and *Klebsiella pneumonia* and two Gram-positive bacteria: *Staphylococcus aureus* and *Enterococcus raffinosus* L. Amongst the tested compounds, compounds **a27** and **a28** exhibited higher antibacterial activity than the standard drugs (Table [13](#Tab13){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR19]\].Table 13Antibacterial activity of some novel pyrazolopyrimidine derivativesCompoundsMIC (µmol/l)*Enterococcus raffinosusStaphylococcus aureus***a27**12.33.8**a28**14.24.2Penicillin G93.524.4

Sriharsha et al. developed a new series of novel 1,3-thiazolidine pyrimidine derivatives and carried out its antibacterial activity against 14 bacterial strains i.e. *Citrobacter* sp., *Escherichia coli, Klebsiella* sp., *Proteus mirabilis, Pseudomonas aeruginosa, S. parathyphi A, S. parathyphi B, Salmonella typhi, S. typhimurium, Shigella boydii, Shigella flexneri, Shigella sonnei, Staphylococcus aureus* and *Streptococcus faecalis.* All compounds with free NH group in the pyrimidine moiety showed significant biological activity against all the standard strains used and in that compounds **a29** and **a30** showed promising activity against 14 human pathogens tested and compared with the ciprofloxacin and bacitracin used as standard drugs (Table [14](#Tab14){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR20]\].Table 14Antibacterial activity (zone of inhibition = mm) of most active compoundsS. noPathogens**a29a30**BacitracinCiprofloxacin**1***Citrobacter* sp.37.16 ± 0.1528.66 ± 0.150.00 ± 0.0019.62 ± 0.18**2***Escherichia coli*36.66 ± 0.1527.83 ± 0.200.00 ± 0.000.00 ± 0.00**3***Klebsiella* sp.32.50 ± 0.1325.50 ± 0.270.00 ± 0.0020.25 ± 0.16**4***Proteus mirabilis*28.66 ± 0.2523.33 ± 0.170.00 ± 0.0018.25 ± 0.16**5***Pseudomonas aeruginosa*30.66 ± 0.1227.83 ± 0.270.00 ± 0.0034.25 ± 0.16**6***S. parathyphi A*34.66 ± 0.1224.50 ± 0.120.00 ± 0.0027.75 ± 0.16**7***S. parathyphi B*32.50 ± 0.1327.83 ± 0.200.00 ± 0.0027.63 ± 0.18**8***Salmonella typhi*29.50 ± 0.2519.66 ± 0.110.00 ± 0.0020.25 ± 0.16**9***S. typhimurium*34.66 ± 0.1223.33 ± 0.170.00 ± 0.0018.75 ± 0.31**10***Shigella boydii*37.50 ± 0.0728.66 ± 0.250.00 ± 0.0017.75 ± 0.16**11***Shigella flexneri*35.66 ± 0.0825.50 ± 0.270.00 ± 0.0027.63 ± 0.18**12***Shigella sonnei*32.50 ± 0.1337.50 ± 0.070.00 ± 0.0021.75 ± 0.16**13***Staphylococcus aureus*37.50 ± 0.0732.50 ± 0.1326.75 ± 0.8418.13 ± 0.48**14***Streptococcus faecalis*38.50 ± 0.1235.66 ± 0.080.00 ± 0.000.00 ± 0.00

Anticancer activity {#Sec4}
-------------------

Cancer is a multifaceted disease that represents one of the leading causes of mortality in developed countries. Worldwide, one in eight deaths are due to cancer and it is the second most common cause of death in the US, exceeded only by heart disease. Chemotherapy is the mainstay for cancer treatment, the use of available chemotherapeutics is often limited due to undesirable side effects. It is important to identify new molecules and new targets for the treatment of cancer \[[@CR17]\].

Shao et al. synthesized a new derivatives of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential antitumour agents. The synthesized 2,4,5-trisubstituted pyrimidine derivatives were evaluated for their antitumour activity against a panel of cancer cell lines including colorectal, breast, lung, ovarian, cervical and pancreatic cancer cells. Among the synthesized derivatives, compound **b1**, possessing appreciable selectivity for CDK9 over other CDKs, is capable of activating caspase 3, reducing the level of Mcl-1 anti-apoptotic protein and inducing cancer cell apoptosis (Table [15](#Tab15){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR21]\].Table 15Anti-proliferative activity of **b1** in human cancer cell linesCompoundHuman cancer cell linesOriginDesignation48 h-MTT GI50 (µM) ± SD**b1**Colon carcinomaHCT-1160.79 ± 0.08Breast carcinomaMCF-70.64 ± 0.08MDA-MB4681.51 ± 0.34Lung carcinomaA5492.01 ± 0.55Ovarian carcinomaA27801.00 ± 0.11Cervical carcinomaHeLa0.90 ± 0.07Pancreatic carcinomaMiacapa-21.25 ± 0.26 Fig. 5Chemical structures of the most active anticancer pyrimidine derivatives (**b1**--**b12**)

Cocco et al. synthesized a new class of 6-thioxopyrimidine derivatives and its molecular structures were confirmed by IR, NMR and elemental analyses study. The synthesized derivatives were evaluated their in vitro anticancer potential against multiple panels of 60 human cancer cell lines by Sulforhodamine B assay. All synthesized 6-thioxopyrimidine derivatives exhibited good anticancer potential, especially, compound **b2** showed the best cytotoxicity (Table [16](#Tab16){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR2]\].Table 16Anticancer activity results of most active compound **b2**CompoundCNS cancer cell lines10^−5^ M concentrationOvarian cancer cell lines10^−5^ M concentration**b2**SF-2682.95IGROV17.71SF-2959.79OVCAR-36.34SF-5393.99OVCAR-43.42SNB-195.42OVCAR-84.92SNB-572.49----U-2513.58----

A new library of sulfonamide derivatives was synthesized and investigated for its in vitro and in vivo antitumor potential by El-Sayed et al. Preliminary biological study revealed that compounds, **b3**, **b4** and **b5** showed the highest affinity to DNA and highest percentage increase in lifespan of mice inoculated with Ehrlich ascites cells over 5-flurouracil was taken as standard drug (Table [17](#Tab17){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR22]\].Table 17In vitro anticancer activity results of active compoundsGroupNormalControl (Ehrlich only)**b3b4b5**5-Fluorouracil% Increase in lifespan over control71.43071.4357.1442.8642.86

Two new class of pyrido\[2,3-*d*\]pyrimidine and pyrido\[2,3-*d*\]\[1,2,4\]triazolo\[4,3-*a*\] pyrimidines were synthesized by Fares et al. The molecular structures of synthesized derivatives were confirmed by physicochemical properties and spectral data (IR, NMR, Mass and elemental analyses) and screened for their anticancer activity against human cancer cell lines i.e. PC-3 prostate and A-549 lung. Some of the tested compounds exhibited high growth inhibitory potential against PC-3 cell, among them, compounds, **b6** and **b7** showed relatively potent antitumor potential (Table [18](#Tab18){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR23]\].Table 18Anticancer activity results of compounds **b6** and **b7**CompoundsCancer cell lines (IC~50~ = µM)A-549PC-3**b6**3.36 ± 0.391.54 ± 0.19**b7**0.41 ± 0.030.36 ± 0.025-Fluorouracil4.21 ± 0.3912.00 ± 1.15

Hu et al. developed a new library of 2,4-diamino-furo\[2,3-*d*\]pyrimidine and carried out its in vitro anticancer activity against A459 and SPC-A-1 cancer cell lines. Their structures were confirmed by 1H-NMR, EI-Ms, IR and elemental analysis. Among them, compound **b8**: ethyl-6-methyl-4-(4-methylpiperazin-1-yl)-2-(phenylamino)furo\[2,3-*d*\] pyrimidine-5-carboxylate was found to be most anticancer one against lung cancer cell line (A459 with IC~50~ 0.8 µM) (Fig. [5](#Fig5){ref-type="fig"}) \[[@CR24]\].

Huang et al. developed a new series of pyrazolo\[3,4-*d*\]pyrimidines using 5-aminopyrazoles with formamide in presence of PBr~3~ as the coupling agent and its chemical structures were characterized by IR, ^1^H/^13^C-NMR, Mass, elemental analyses data. The synthesized compounds were screened their in vitro antiproliferative potential by MTT assay against human cancer cell line viz. NCI-H226 (lung carcinoma) and NPC-TW01 (nasopharyngeal carcinoma). From this series, compounds, **b9**, **b10**, **b11** and **b12** possessed better potency against NCI-H226 and NPC-TW01 cancer cells (Table [19](#Tab19){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR25]\].Table 19Antiproliferative results of active compounds (**b9**--**b12**)CompoundsCancer cell lines (GI~50~ = µM)NCI-H226NPC-TW01**b9**1823**b10**2930**b11**3935**b12**3736

Song et al. synthesized a new library of fluorinated pyrazolo\[3,4-*d*\]pyrimidine derivatives by microwave (MW) irradiation method and evaluated its in vitro antitumor potential against human leukaemia (HL-60) cancer cell line by MTT assay. The preliminary results demonstrated that some of compounds exhibited potent antitumor inhibitory potential than doxorubicin (standard drug), especially compounds, **b13** and **b14** exhibited higher antitumor activity due to presence of CF group in its molecule structure (Table [20](#Tab20){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR26]\].Table 20Antitumor potential results of compounds **b13** and **b14**CompoundsHuman leukaemia (HL-60) cancer cell\
IC~50~ = µmol/l**b13**0.08**b14**0.21Doxorubicin0.55 Fig. 6Chemical structures of the most active anticancer pyrimidine derivatives (**b13**--**b23**)

Tangeda and Garlapati, developed new molecules of pyrrolo\[2,3-*d*\]pyrimidine and screened its in vitro anticancer activity against HCT116 colon cancer cell line. Especially, compounds, **b15** and **b16** were found to be most potent ones against HCT116 cell line with IC~50~ value of 17.61 and 17.60 µM respectively which is comparable with 5-fluorouracil (IC~50~ = 3.03 µM) (Fig. [6](#Fig6){ref-type="fig"}) \[[@CR27]\].

Kurumurthy et al. prepared a novel class of alkyltriazole tagged pyrido\[2,3-*d*\] pyrimidine derivatives and its molecular structure were confirmed by IR, NMR, Mass and elemental analyses. The synthesized derivatives were evaluated their in vitro anticancer activity against three cancer cell lines i.e. U937 (human leukemic monocytic lymphoma), THP-1 (human acute monocytic leukemia) and Colo205 (human colorectal cancer) using MTT assay. Among the synthesized molecules, compounds **b17** and **b18** exhibited better anticancer activity than the standard etoposide (Table [21](#Tab21){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR28]\].Table 21In vitro cytotoxicity of pyrido\[2,3-*d*\]pyrimidine derivatives against U~937~, THP-1 and Colo205 cancer cell linesCompoundsIC~50~ (µg/ml)U~937~THP-1Colo205**b17**8.16 ± 0.6816.91 ± 1.4219.25 ± 1.46**b18**6.20 ± 0.6811.27 ± 1.6715.01 ± 1.54Etoposide (positive control)17.94 ± 1.192.16 ± 0.157.24 ± 1.26

Liu et al. synthesized two series of thieno\[3,2-*d*\]pyrimidine molecules containing diaryl urea moiety and screened their anticancer potential. The preliminary investigation showed that most compounds displayed good to excellent potency against four tested cancer cell lines compared with GDC-0941 and sorafenib as standard drugs. In particular, the most promising compound **b19** showed the most potent antitumor activities with IC~50~ values of 0.081, 0.058, 0.18 and 0.23 µM against H460, HT-29, MKN-45 and MDA-MB-231 cell lines, respectively (Fig. [6](#Fig6){ref-type="fig"}) \[[@CR29]\].

Zhu et al. developed a series of 2,6-disubstituted-4-morpholinothieno\[3,2-*d*\]pyrimidine molecules and demonstrated its in vitro cytotoxic activity against H460, HT-29, MDA-MB-231, U87MG and H1975 cancer cell lines. Most of the target compounds exhibited moderate to excellent activity to the tested cell lines. The most promising compound **b20** is more active than the standard drug (Table [22](#Tab22){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR30]\].Table 22Cytotoxicity of compound **b20**CompoundsIC~50~ = (µmol/l)H460HT29MDA-MB-231U87MGH1975**b20**0.840.232.521.8028.82PAC-13.570.976.11NDND*ND* not determined

2,4,5-Substituted pyrimidine molecules were prepared and evaluated for their anticancer activity against different human cancer cell lines (A549, Calu-3, H460, SK-BR3, SGC-7901 and HT29) by Xie et al. Among the synthesized molecules, compounds **b21** showed good inhibition of several different human cancer cell lines with IC~50~ values from 0.024 to 0.55 µM (Table [23](#Tab23){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR31]\].Table 23In vitro anticancer activity of compound **b21**CompoundHuman cancer cell lines (IC~50~ = µM)A549Calu-3H460SK-BR3SGC-7901HT29**b21**0.550.500.120.300.300.090Adriamycin0.025--------0.018Docetaxel--0.100.0097--0.0084--GW572016------0.017----

Al-Issa, developed a new series of fused pyrimidines and related heterocycles and evaluated its in vitro antitumor activity against human liver cancer cell line (HEPG2). Structures of all synthesized compounds were supported by spectral and elemental analyses. Among the synthesized compounds, compounds **b22** and **b23** showed significant in vitro antitumor activity (IC~50~, 17.4, 23.6 µg/ml) (Fig. [6](#Fig6){ref-type="fig"}) \[[@CR32]\].

Mohareb et al. developed a new class of fused pyran, pyrimidine and thiazole molecules and evaluated its in vitro anticancer potential against cancer cell lines i.e. NUGC- gastric; DLDI-colon; HA22T-liver; HEPG2-liver; HONEI-nasopharyngeal carcinoma; HR-gastric; MCF-breast and WI38-normal fibroblast cells. In this study, compounds, **b24** and **b25** exhibited more anticancer potential (Table [24](#Tab24){ref-type="table"}, Fig. [7](#Fig7){ref-type="fig"}) \[[@CR33]\].Table 24Anticancer activity results of **b24** and **b25**CompoundsCytotoxicity (IC~50~ in nM)NUGCDLDIHA22THEPG2HONEIMCFWI38**b24**180740234837644269Na**b25**406482328260173NaCHS 828252315206712451518Na Fig. 7Chemical structures of the most active anticancer pyrimidine derivatives (**b24**--**b32**)

A new series of novel pyrazolo\[3,4-*b*\]pyridine and pyrimidine functionalized 1,2,3-triazole derivatives were prepared from 6-trifluoro methyl pyridine-2(1*H*)one by Nagender et al. and screened for its cytotoxicity against four human cancer cell lines such as A549-Lung (CCL-185), MCF7-Breast (HTB-22), DU145-Prostate (HTB-81) and HeLa-Cervical (CCL-2). Among them, compounds, **b26**, **b27** and **b28** showed promising cytotoxicity (Table [25](#Tab25){ref-type="table"}, Fig. [7](#Fig7){ref-type="fig"}) \[[@CR17]\].Table 25In vitro cytotoxicity of most active compoundsCompoundsIC~50~ values (in µM)A549MCF7DU145HeLa**b26**4.1 ± 0.12--4.7 ± 0.18--**b27**5.7 ± 0.2224.7 ± 0.166.3 ± 0.2122.7 ± 0.11**b28**4.2 ± 0.3137.2 ± 0.315.8 ± 0.1434.3 ± 0.325-Fluorouracil1.3 ± 0.111.4 ± 0.091.5 ± 0.121.3 ± 0.14

Kumar et al. developed a new library of triazole/isoxazole functionalized 7-(trifluoromethyl)pyrido\[2,3-*d*\]pyrimidine derivatives and screened their anticancer activity against four human cancer cell lines using nocodazole as standard. Compounds **b29** and **b30** showed highest activity against PANC-1 (pancreatic cancer) and A549 (lung cancer) cell lines respectively (Table [26](#Tab26){ref-type="table"}, Fig. [7](#Fig7){ref-type="fig"}) \[[@CR34]\].Table 26Anticancer activity of triazole/isoxazole functionalized pyridopyrimidine derivativesCompoundsGI~50~ values in µMMDA MB-231PANC1A549HeLa**b29**2.21 ± 0.080.02 ± 0.010.86 ± 0.030.81 ± 0.02**b30**2.83 ± 0.050.73 ± 0.010.03 ± 0.010.93 ± 0.03Nocodazole0.042 ± 0.0010.029 ± 0.0030.08 ± 0.0010.063 ± 0.002

A new class of novel thieno\[3,2-*d*\]pyrimidine derivatives was synthesized by Liu et al. and studied for its anticancer potential against selected cancer cell lines viz: H460, HT-29, MKN-45 and MDA-MB-231. Most of compounds displayed good to excellent potency against four tested cancer cell lines as compared with GDC-0941 and sorafenib.

In this study, compound **b31** was found to be most active anticancer one (Table [27](#Tab27){ref-type="table"}, Fig. [7](#Fig7){ref-type="fig"}) \[[@CR35]\].Table 27Cytotoxicity of compound **b31**CompoundIC~50~ (µmol/l) ± SDH460HT-29MKN-45MDA-MB-231**b31**0.057 ± 0.0110.039 ± 0.0080.25 ± 0.0190.23 ± 0.020GDC-09410.87 ± 0.200.86 ± 0.0810.60 ± 0.120.28 ± 0.06Sorafenib2.19 ± 0.113.61 ± 0.362.32 ± 0.350.94 ± 0.13

Lv et al. synthesized a new series of 2-phenylpyrimidine coumarin derivatives and evaluated its in vitro antiproliferative activity against CNE2, KB and Cal27 cancer cell lines. The results showed that most of the derivatives had a favorable effect on resisting tumor cell proliferation, among them, compound **b32** exhibited the best antiproliferative activity and comparable to the standard drug (Table [28](#Tab28){ref-type="table"}, Fig. [7](#Fig7){ref-type="fig"}) \[[@CR36]\].Table 28In vitro anticancer activity of the synthesized compoundCompoundIC~50~ (µM)CNE2KBCal27**b32**1.92 ± 0.133.72 ± 0.541.97 ± 0.51Doxorubicin2.12 ± 0.563.04 ± 0.871.56 ± 0.64

Antiviral activity {#Sec5}
------------------

Antiviral nucleoside compounds inhibit viral genome replication by acting as mimetics of the natural nucleosides. Nucleoside analogues (NAs) can either act as chain terminators after being incorporated into growing DNA/RNA strands and/or inhibit the viral polymerase function by competition with the natural nucleoside 50-triphosphate substrate \[[@CR3]\].

A new library of 4*H*,6*H*-\[1,2,5\]oxadiazolo\[3,4-*d*\]pyrimidine-5,7-dione 1-oxide nucleoside was synthesized by Xu et al. and screened for its in vitro anti-vesicular stomatitis virus (VSV) activity in Wish cell. All the synthesized derivatives showed obvious anti-VSV potential whereas, compound **c1** with ribofuranoside enhanced the anti-VSV potential by approximately 10--18 times compared to didanosine and acyclovir (standard drugs), respectively (Table [29](#Tab29){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}) \[[@CR37]\].Table 29Experimental antiviral results of compound **c1**CompoundToxicity for wish cells and antivirus effect (TC0 µmol/l)ED~50~Model 1Model 2**c1**209578148100Acyclovir34141411----Didanosine2646792---- Fig. 8Chemical structures of the most active antiviral pyrimidine derivatives (**c1**--**c10**)

Hockova et al. synthesized a new series of 2,4-diamino-5-cyano-6\[2-(phosphono methoxy)ethoxy\]pyrimidine derivatives and evaluated its antiviral activity. The 5-cyano and 5-formyl derivatives (**c2**--**c4**) showed pronounced antiretroviral activity, comparable to that of the reference drugs adefovir and tenofovir (Table [30](#Tab30){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}) \[[@CR38]\].Table 30Antiviral activity results of test compounds (**c2**--**c4)** in cell cultureCompoundsEC~50~^a^ (µmol/ml)CC~50~^b^HIV (III~B~)HIV-2 (ROD)MSV(µmol/ml) (CEM)**c2**0.0110.00450.0095≥ 0.3**c3**0.00450.00270.021≥ 0.3**c4**0.0800.050--≥ 0.2Adefovir0.00330.00660.00220.056Tenofovir0.00120.00140.00460.14^a^50% effective concentration; ^b^ 50% cytostatic concentration

Tian et al. developed a novel library of 5,7-disubstituted pyrazolo\[1,5-*a*\]pyrimidine molecules and carried out its anti-HIV potential. From the series, compound **c5**: 4-(7-(mesityloxy)-4,5-dihydropyrazolo\[1,5-*a*\]pyrimidin-5-ylamino)benzonitrile was found to be the most active one (Fig. [8](#Fig8){ref-type="fig"}) with an EC~50~ = 0.07 µM against wild-type HIV-1 and very high selectivity index (SI, 3999) than the reference drugs (nevirapine and delavirdine) \[[@CR39]\].

A new class of novel acyclic nucleosides in the 5-alkynyl and 6-alkylfuro\[2,3-*d*\] pyrimidines was synthesized by Amblard et al. and screened for its antiviral activity against human immunodeficiency virus (HIV), herpes simplex virus (HSV-1). Compounds, **c6** and **c7** exhibited moderate antiviral activity (Table [31](#Tab31){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}) \[[@CR40]\].Table 31Antiviral activity results (µM) of compounds **c6** and **c7**CompoundsAnti-HIV-1 activity in PBMCsHSV-1 plaque reduction assayEC~50~EC~90~EC~50~EC~90~**c6**2.719.86.316.4**c7**4.913.074.846.2AZTa0.0160.20\> 10\> 10Acyclovira\> 100\> 1000.110.69

A series of pyrazole and fused pyrazolo pyrimidines was synthesized by Rashad et al. and studied for their antiviral activity against hepatitis-A virus (HAV) and herpes simplex virus type-1 (HSV-1). The substituted pyrazole and fused pyrazolopyrimidine derivatives, **c8** and **c9** revealed higher anti-HSV-1 activity at concentration of 10 µg/10^5^ cells and antiviral results are compared with amantadine and acyclovir (Fig. [8](#Fig8){ref-type="fig"}) \[[@CR41]\].

Sari et al. developed a new library of dihydropyrimidine α,γ-diketobutanoic acid molecules and screened its antiviral potential. Among the series, compound **c10** ((*Z*)-ethyl-4-benzyl-1-(4-(3-hydroxy-4-isopropoxy-4-oxobut-2-enoyl)benzyl)-6-methyl-2-oxo-1,2-dihydro pyrimidine-5-carboxylate) was found to be most active anti-HIV agent (Table [32](#Tab32){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}) \[[@CR42]\].Table 32Antiviral activity results of compound **c10**CompoundEC~50~ (µM)**c10**17.2AZT0.0074

Antimalarial activity {#Sec6}
---------------------

Malaria is the most serious and widespread parasitic disease because of its prevalence, virulence and drug resistance, having an overwhelming impact on public health in developing regions of the world. *Plasmodium falciparum* is the main cause of severe clinical malaria and death. Endemic mapping indicates that *P. falciparum* and *P. vivax* account for 95% of the malarial infections \[[@CR43]\]. According to a WHO report, malaria accounted for 207 million cases and an estimated 627,000 deaths worldwide in 2013 \[[@CR8]\].

Kumar et al. synthesized a new series of 4-aminoquinoline-pyrimidine hybrids and evaluated its antimalarial potential. Several compounds showed promising in vitro antimalarial activity against both CQ sensitive and CQ-resistant strains with high selectivity index. The in vitro evaluation of these hybrids against D6 and W2 strains of *P. falciparum* depicted the antimalarial activity in the nanomolar range. Also, these hybrids exhibited high selectivity indices and low toxicity against the tested cell lines. Compounds (**d1**, **d2** and **d3)** (Fig. [9](#Fig9){ref-type="fig"}) exhibited very potent antimalarial activity with IC~50~ = 0.033, 0.019 and 0.028 µM respectively which were comparable to the standard drug chloroquine (IC~50~ = 0.035 µM) against CQ-sensitive strain \[[@CR8]\].Fig. 9Chemical structures of the most active antimalarial pyrimidine derivatives (**d1**--**d12**)

Maurya et al. developed a new series of novel *N*-substituted 4-aminoquinoline-pyrimidine hybrids via simple and economic route and evaluated its antimalarial activity. Most compounds showed potent antimalarial activity against both CQ-sensitive and CQ-resistant strains with high selectivity index. All the compounds were found to be non-toxic to the mammalian cell lines. The most active compound **d4** was analyzed for heme binding activity using UV spectrophotometer. Compound **d4** was found to interact with heme and a complex formation between compound **d4** and heme in a 1:1 stoichiometry ratio was determined using job plots. The interaction of these hybrids was also investigated by the molecular docking studies in the binding site of wild type Pf-DHFR-TS and quadruple mutant Pf-DHFR-TS (Table [33](#Tab33){ref-type="table"}, Fig. [9](#Fig9){ref-type="fig"}) \[[@CR44]\].Table 33In vitro antimalarial activity of AQ-furfural-2-carbaldehyde-pyrimidine hybridsCompound*P. falciparum* D6*P. falciparum* W2VERO cellsResistance indexIC~50~ (µM)(SI)IC~50~ (µM)(SI)**d4**0.038 ± 0.000\> 263.150.040 ± 0.001\> 250.0NC1.05Chloroquine0.011 ± 0.004\> 909.090.317 ± 0.051\> 31.54NC28.81Pyrimethamine0.009 ± 0.003\> 1111.1NA--NC--Artemisinin0.045 ± 0.001\> 222.220.023 ± 0.001434.78NC0.511

Agarwal et al. developed a new series of 2,4,6-trisubstituted-pyrimidines and evaluated its in vitro antimalarial activity against *Plasmodium falciparum*. All the synthesized compounds showed good antimalarial activity against *Plasmodium falciparum* whereas, compound **d5** exhibited higher antimalarial activity than pyrimethamine used as standard drug (Table [34](#Tab34){ref-type="table"}, Fig. [9](#Fig9){ref-type="fig"}) \[[@CR43]\].Table 34Antimalarial in vitro activity against *P. falciparum*CompoundMIC (µg/ml)**d5**0.25Pyrimethamine10

Pretorius et al. synthesized a new library of quinoline--pyrimidine hybrids and evaluated its in vitro antimalarial activity against the D10 and Dd2 strains of *Plasmodium falciparum*. The compounds were all active against both strains. However, hybrid (**d6**, Fig. [9](#Fig9){ref-type="fig"}) featuring piperazine linker stood as the most active of all. It was found as potent as CQ and PM against the D10 strain and possessed a moderately superior potency over CQ against the Dd2 strain (IC~50~: 0.157 vs 0.417 µM) and also displayed activity comparable to that of the equimolar fixed combination of CQ and PM against both strains \[[@CR45]\].

Azeredo et al. synthesized a new series of 7-aryl aminopyrazolo\[1,5-*a*\]pyrimidine derivatives with different combinations of substituent's at positions 2-,5- and 7- of the pyrazolo\[1,5-*a*\]pyrimidine ring. The compounds were tested against *Plasmodium falciparum*, as antimalarials in mice with *P. berghei* and as inhibitors of *Pf*DHODH. From this series, compounds, **d7**, **d8**, **d9** and **d10** were found to be the most active ones (Table [35](#Tab35){ref-type="table"}, Fig. [9](#Fig9){ref-type="fig"}) \[[@CR46]\].Table 35In vitro antimalarial activity results of active compoundsCompounds(%) Activity *Pf*DHODHIC~50~ against *Pf*DHODH (µM)**d7**67.474 ± 0.0026 ± 1**d8**41 ± 34 ± 1**d9**77 ± 1--**d10**60 ± 30.16 ± 0.01

A series of *N*-aryl and heteroaryl sulfonamide derivatives of meridianins were prepared by Yadav et al. and screened for its antimalarial activity against D6 and W2 strains of *Plasmodium falciparum*. Especially, compounds, **d11** and **d12** displayed promising antiplasmodial activity and comparable to the standard drugs (Table [36](#Tab36){ref-type="table"}, Fig. [9](#Fig9){ref-type="fig"}) \[[@CR47]\].Table 36In vitro antimalarial activity of *N*-aryl and heteroaryl sulfonamide derivativesCompounds*P. falciparum* (IC~50~ in µM (µg/ml))*P. falciparum* (D6)*P. falciparum* (W2)IC~50~SIIC~50~SI**d11**4.86 (2.3)\> 10.86.39 (3.02)\> 8.2**d12**2.56 (1.38)\> 183.41 (1.84)\> 13.5Artemisinin\< 0.09 (\< 0.03)--\< 0.09 (\< 0.03)--Chloroquine\< 0.08 (\< 0.03)--0.72 (0.23)--

Anti-inflammatory activity {#Sec7}
--------------------------

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used therapeutics, primarily for the treatment of pain, rheumatic arthritis and various types of inflammatory conditions. However, their use is mainly restricted by their well known and serious adverse gastrointestinal side effects such as gastroduodenal erosions, ulcerations and nephrotoxicity \[[@CR6]\].

Tozkoparan et al. synthesized a new class of 2-benzylidene-7-methyl-3-oxo-5-(substituted phenyl)-2,3-dihydro-5*H*-thiazolo\[3,2-*a*\]pyrimidine-6-carboxylic acid methyl esters and evaluated its anti-inflammatory activity by carrageenan induced edema test using indomethacin as reference drug. Test results revealed that compounds, **e1**, **e2**, **e3**, **e4** exerted moderate anti-inflammatory activity at the 100 mg/kg dose level compared with indomethacin (Table [37](#Tab37){ref-type="table"}, Fig. [10](#Fig10){ref-type="fig"}) \[[@CR5]\].Table 37Anti-inflammatory activity in percentage (%) of synthesized compounds (**e1**--**e4**)CompoundsAnti-inflammatory activity (%)^a^**e1**41**e2**38**e3**16**e4**28Indomethacin32^a^ 100 mg/kg p.o. (*n *= 6) Fig. 10Chemical structures of the most active anti-inflammatory pyrimidine derivatives (**e1**--**e15**)

Two new series of thieno\[2′,3′:4,5\]pyrimido\[1,2-*b*\]\[1,2,4\]triazines and thieno\[2,3-*d*\]\[1,2,4\]triazolo\[1,5-*a*\]pyrimidines were synthesized by Ashour et al. and evaluated for their anti-inflammatory and analgesic activity using diclofenac as reference drug. In general, the thieno\[2,3-*d*\]\[1,2,4\]triazolo\[1,5-*a*\]pyrimidine derivatives exhibited better anti-inflammatory activity than the thieno\[2′,3′5′:4,5\]pyrimido\[1,2-*b*\]\[1,2,4\]triazines. The thienotriazolo pyrimidine derivatives, **e5, e6** and **e7** (Fig. [10](#Fig10){ref-type="fig"}) were proved to display distinctive anti-inflammatory activity at the acute and sub acute models as well as good analgesic profile with a delayed onset of action. The anti-inflammatory screening results are presented in Tables [38](#Tab38){ref-type="table"} and [39](#Tab39){ref-type="table"} \[[@CR6]\].Table 38Anti-inflammatory activity of compounds (**e5**--**e7**) in formal in induced rat paw edema bioassay (sub-acute inflammatory model)CompoundsVolume of edema (ml)^a^01st day8th day**e5**0.31 ± 0.010.51 ± 0.03^b^ (44)^c^0.68 ± 0.02^b^ (31)**e6**0.35 ± 0.020.54 ± 0.01^b^ (47)0.67 ± 0.02^b^ (40)**e7**0.33 ± 0.020.15 ± 0.01^b^ (50)0.67 ± 0.02^b^ (37)Control0.32 ± 0.010.68 ± 0.010.86 ± 0.03Diclofenac0.32 ± 0.020.52 ± 0.02^b^ (44)0.64 ± 0.02^b^ (40)^a^Values are expressed as mean ± S.E. (Number of animals N = 5 rats)^b^Significantly different compared to corresponding control P ≤ 0.05^c^Between parentheses (percentage anti-inflammatory activity %) Table 39Anti-inflammatory activity of the fused thienopyrimidines in formalin-induced rat paw edema bioassay (acute inflammatory model)CompoundsVolume of edema (ml)^a^ED~50~ (mg/kg)01 h2 h4 h**e5**0.31 ± 0.010.44 ± 0.02^b^ (38)^c^0.49 ± 0.01^b^ (43)0.52 ± 0.02^b^ (52)23.45^d^**e6**0.35 ± 0.020.46 ± 0.01^b^ (47)0.50 ± 0.01^b^ (53)0.54 ± 0.02^b^ (56)28.15**e7**0.33 ± 0.020.46 ± 0.01^b^ (42)0.53 ± 0.01^b^ (37)0.59 ± 0.02^b^ (40)26.12Control0.32 ± 0.010.55 ± 0.010.64 ± 0.020.76 ± 0.01--Diclofenac0.32 ± 0.020.45 ± 0.01^b^ (38)0.50 ± 0.02^b^ (43)0.53 ± 0.02^b^ (52)25.13^a^Values are expressed as mean ± SE (number of animals N = 5 rats)^b^Significantly different compared to corresponding control P ≤ 0.05^c^Between parentheses (percentage anti-inflammatory activity %)^d^ED~50~ is the effective dose calculated after 2 h

Yejella and Atla, synthesized a new series of 2,4,6-trisubstituted pyrimidines and screened its in vivo anti-inflammatory activity by carrageenan induced rat paw edema model. Compounds, **e8**: 2-amino-4-(4-aminophenyl)-6-(2,4-dichlorophenyl)pyrimidine and **e9**: 2-amino-4-(4-aminophenyl)-6-(3-bromophenyl)pyrimidine were found to be the most potent anti-inflammatory agents compared with ibuprofen (Table [40](#Tab40){ref-type="table"}, Fig. [10](#Fig10){ref-type="fig"}) \[[@CR48]\].Table 40Anti-inflammatory activity of pyrimidine derivativesComp.Percent inhibition ± SEM at various time intervals0.5 h1.0 h2.0 h3.0 h4.0 h6.0 h**e8**15.22 ± 0.68\*50.45 ± 1.23\*87.23 ± 2.61\*62.51 ± 2.33\*56.94 ± 1.7948.39 ± 2.65**e9**18.26 ± 0.68\*49.35 ± 1.41\*86.99 ± 2.62\*62.13 ± 2.25\*53.32 ± 2.0142.11 ± 2.75Ibuprofen20.26 ± 0.90\*53.95 ± 0.97\*97.09 ± 2.86\*79.97 ± 2.38\*67.93 ± 2.22\*58.02 ± 1.87\*All values are represented as mean ± SEM (*n *= 6). \**P *\< 0.01 compared to saline control group. One-way ANOVA, Dunnett's *t* test. Dosage: Ibuprofen-10 mg/kg and test compounds-10 mg/kg body weight by orally

Zhou et al. synthesized a new series of imidazo\[1,2-*a*\]pyrimidine derivatives and screened its anti-inflammatory potential with selective cyclooxygenase-2 (COX-2) inhibitors. In this series, compound **e10** exhibited potent activity (63.8%) than ibuprofen (44.3%). The human whole blood assay still revealed that **e10** (Fig. [10](#Fig10){ref-type="fig"}) has selective COX-2 inhibition (IC~50~ = 13 µmol/l) which is 13 times more potent than its inhibitory activity to COX-1 (IC~50~ = 170 µmol/l) and swollen inhibition 63.8%. The results indicated that imidazo\[1,2-*a*\] pyrimidine compounds keep moderate anti-inflammatory activity as compared to ibuprofen (standard drug) \[[@CR49]\].

Gondkar et al. prepared a new class of substituted 1,2,3,4-tetrahydropyrimidine and screened its in vitro anti-inflammatory activity by inhibition of protein denaturation method using diclofenac (standard drug). The results revealed that almost all the tested compounds showed potent anti-inflammatory potential. All synthesized derivatives were tested their in vitro anti-inflammatory activity using inhibition of albumin denaturation technique compared to standard diclofenac. Derivatives, **e11**, **e12**, **e13**, **e14** and **e15** (Fig. [10](#Fig10){ref-type="fig"}) showed significant in vitro anti-inflammatory activity with % inhibition of albumin denaturation 98, 97, 90, 94, and 96% respectively \[[@CR50]\].

Keche et al. developed a new series of novel 4-(3-(trifluoromethyl)phenylamino-6-(4-(3-arylureiodo/arylthioureido/arylsulfonamido)-pyrimidine derivatives by the sequential Suzuki cross coupling and screened for their anti-inflammatory activity. Among all the synthesized derivatives, compounds, **e16**, **e17**, **e18**, **e19**, **e20** and **e21** were found to have moderate to potent anti-inflammatory activity and compared to dexamethasone used as reference drug (Table [41](#Tab41){ref-type="table"}, Fig. [11](#Fig11){ref-type="fig"}) \[[@CR51]\].Table 41Anti-inflammatory activity of novel pyrimidine derivativesCompounds% Inhibition at 10 µM NF-αIL-6**e16**7896**e17**7190**e18**6180**e19**6882**e20**5062Dexamethasone7286 Fig. 11Chemical structures of the most active anti-inflammatory pyrimidine derivatives (**e16**--**e24**)

Mohamed et al. synthesized a new library of thio containing pyrrolo\[2,3-*d*\]pyrimidine derivatives and carried out its in vitro anti-inflammatory potential using the carrageenan-induced rat paw oedema assay. The potency and duration of action was compared to ibuprofen was taken as standard drug. From tested compounds, compounds **e21**, **e22** and **e23** showed best anti-inflammatory activity (Table [42](#Tab42){ref-type="table"}, Fig. [11](#Fig11){ref-type="fig"}) \[[@CR52]\].Table 42In vivo anti-inflammatory activityCompoundsOedema induced by carrageenan (% oedema % inhibition relative to control)1 h2 h3 h4 hSwel% inhSwel% inhSwel% inhSwel% inh**e21**0.20610.430.10161.150.142^c^73.90.132^b^79.04**e22**0.19614.780.182300.022^c^95.580.28267.43**e23**0.2166.080.012^b^95.380.024^c^95.950.202^a^76.82Ibuprofen0.2166.080.14450.214^b^60.660.192^a^69.52As indicated: ^a^ P \< 0.05; ^b^ P \< 0.01; ^c^ P \< 0.001

Sondhi et al. synthesized new derivatives of pyrimidine and screened their anti inflammatory activity carried out using carrageenin-induced paw oedema assay. All compounds exhibited good activity whereas, compound **e24** was found to be most active one comparable to the standard drug ibuprofen (Table [43](#Tab43){ref-type="table"}, Fig. [11](#Fig11){ref-type="fig"}) \[[@CR53]\].Table 43Anti-inflammatory of compound **e24**CompoundDose mg/kg poAnti-inflammatory activity %**e24**10065Ibuprofen10066.8

Antioxidant activity {#Sec8}
--------------------

Oxidative stress seems to play a significant role in various human diseases, including cancers. Antioxidant compounds are the agents that neutralize free radicals, which scavenge reactive oxygen species, may have potent value in preventing the onset and propagation of oxidative diseases such as neurovascular, cardiovascular diseases. Pyrimidine and its derivatives have recently attracted the attention of medicinal chemists in exploring their potential as antioxidant agents \[[@CR1]\].

Bhalgat et al. developed a new class of novel pyrimidines and its triazole fused derivatives and investigated its in vitro antioxidant by various methods as scavenging of hydrogen peroxide, scavenging of nitric oxide radical and lipid per oxidation inhibitory activity. Compounds, **f1** showed good antioxidant activity as compared to standard by scavenging of nitric oxide radical and hydrogen peroxide, while **f2** showed most potent antioxidant activity by scavenging of nitric oxide (Table [44](#Tab44){ref-type="table"}, Fig. [12](#Fig12){ref-type="fig"}) \[[@CR7]\].Table 44Antioxidant activity (IC-50 values) of compounds **f1** and **f2**CompoundIC-50 (mean ± SD)^a^ (µg/ml)Scavenging of nitric oxide radicalScavenging of hydrogen peroxideLipid peroxidation inhibitory activity**f1**51 ± 0.05841 ± 0.08740 ± 0.121**f2**47 ± 0.05252 ± 0.27943 ± 0.333Standard56 ± 0.08738 ± 0.12126 ± 0.333^a^Average of three determination Fig. 12Chemical structures of the most active antioxidant pyrimidine derivatives (**f1**--**f10**)

Kotaiah et al. synthesized new molecules of novel 1,2,4-triazolo\[3,4-*b*\]\[1,3,4\]thiadiazol-6-yl)selenopheno\[2,3-*d*\]pyrimidines with substituted anilines and benzoic acid. The antioxidant activity of the synthesized compounds was evaluated by DPPH, NO and H~2~O~2~ radical scavenging methods. In this series, compounds, **f3**, **f4** and **f5** showed promising antioxidant activity compared to standard drug (Table [45](#Tab45){ref-type="table"}, Fig. [12](#Fig12){ref-type="fig"}) \[[@CR54]\].Table 45Antioxidant activity of most compoundsCompoundsScavenging activity (IC~50~ µg/ml)DPPHNOH~2~O~2~**f3**11.02 ± 0.2713.72 ± 1.2615.38 ± 0.96**f4**10.41 ± 0.2312.74 ± 0.1817.08 ± 0.12**f5**9.46 ± 0.918.20 ± 1.6012.54 ± 1.17AA12.27 ± 0.8614.62 ± 0.9715.24 ± 0.44BHT16.53 ± 1.7419.06 ± 1.0417.82 ± 0.28Lower IC~50~ values indicate higher radical scavenging activity*AA* ascorbic acid, *BHT* butylated hydroxy toluene

Mohana et al. reported a new series of pyrimidine derivatives and evaluated its antioxidant activity by DPPH method. The structures of all the new compounds are established on the basis of FT-IR, ^1^H-NMR and Mass spectral data. All the compounds showed DPPH radical scavenging activity, whereas, compounds, **f6**, **f7** and **f8** exhibited best radical scavengers due to presence of electron donating methoxy group at different position (*ortho, meta* and *para*) (Table [46](#Tab46){ref-type="table"}, Fig. [12](#Fig12){ref-type="fig"}) \[[@CR55]\].Table 46DPPH radical scavenging activity of the tested compoundsCompoundsScavenging effect (%)Concentration of the tested compounds (µg/ml)100150200**f6**51.160.868.1**f7**35.246.352.1**f8**32.243.454.8Ascorbic acid73.085.398.2

Quiroga et al. developed a new library of 5-aryl-4-oxo-3,4,5,8-tetrahydropyrido\[2,3-*d*\] pyrimidine-7-carboxylic acids and carried out their antioxidant activity by DPPH (1,1-diphenyl-2-picryl-hydrazyl) radical scavenging assay. Compounds **f9** and **f10** showed antioxidant properties and compared to standard drugs (Table [47](#Tab47){ref-type="table"}, Fig. [12](#Fig12){ref-type="fig"}) \[[@CR56]\].Table 47Free radical scavenging (FRS~50~) for the tested pyrido\[2,3-*d*\]pyrimidines (**f9** and **f10**)CompoundsFRS~50~ (µg/ml)Mean%RSD**f9**36710**f10**47210Asc. acid1.112Quercetin3.47

Antileishmanial activity {#Sec9}
------------------------

Leishmaniasis, a vector-borne parasitic disease, is a major cause of concern in developing countries. The disease is caused by more than 20 species of protozoan *Leishmania* and transmitted by the bite of female phlebotomine sand flies. Leishmaniasis has traditionally been classified into three major clinical forms: visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL) which differs in immunopathologies and degree of morbidity and mortality. VL caused by *Leishmania donovani* is the most severe form of leishmaniasis and is usually fatal in the absence of treatment. Most of the first line drugs available for the treatment of leishmaniasis such as sodium stibogluconate, meglumine antimoniate, pentamidine etc. cause serious side effects and toxicity \[[@CR57]\].

A new series of substituted aryl pyrimidine derivatives was synthesized by Suryawanshi et al. and evaluated for its in vitro antileishmanial potential against intracellular amastigotes of *Leishmania donovani* using reporter gene luciferase assay. All synthesized compounds showed promising IC~50~ values ranging from 0.5 to 12.9 µM. Selectivity indices (S.I.) of all these compounds are far better than sodium stibogluconate (SSG) and miltefosine used as standard drugs. On the basis of good selectivity indices compounds were further screened their in vivo antileishmanial activity against *L. donovani*/hamster model. Compounds, **g1**, **g2** and **g3** showed good inhibition (Table [48](#Tab48){ref-type="table"}, Fig. [13](#Fig13){ref-type="fig"}) of parasitic multiplication that is 88.4, 78.1 and 78.2%, respectively at a daily dose of 50 mg/kg × 5 days, when administered intraperitoneally \[[@CR57]\].Table 48In vitro and in vivo antileishmanial activity and cytotoxicity results of synthetic pyrimidine derivativesCompoundsIn vitro assessmentSelectivity index\
CC~50~/IC~50~In vivo activity (dose---50 mg/kg × 5 days, ip^b^)\
% Inhibition ± SDIC~50~ (µM)CC~50~ (µM)**g1**2.0 ± 0.1375.9 ± 5.118888.4 ± 10.6**g2**0.5 ± 0.157.8 ± 5.911678.1 ± 17.7**g3**2.7 ± 0.5345.4 ± 19.612878.2 ± 4.4SSG^a^59.8 ± 7.5\> 400 ± 0\> 788.5 ± 4.4Miltefosine^c^12.5 ± 0.954.7 ± 6.9498.1 ± 1.0IC~50~ and CC~50~ values are the mean ± SD of two independent experimentsThe selectivity index is defined as the ratio of CC~50~ on vero cells to IC~50~ on *L. donovani* intramacrophagic amastigotes^a^SSG = sodium stibogluconate (40 mg/kg × 5 days, ip)^b^ip = intraperitonial; ^c^ Miltefosine (30 mg/kg × 5 days, po) used as a reference drugs Fig. 13Chemical structures of the most active antileishmanial pyrimidine derivatives (**g1**--**g7**)

Pandey et al. synthesized some novel terpenyl pyrimidine from *α/β*-ionone keteneacetals and screened their in vivo leishmanicidal activity against amastigote stage of *Leishmania donovani* was determined in Golden hamsters (*Mesocricotus aurctus*) infected with HOM/IN/80/DD8 strain of *L. donovani*. The compounds, **g4**, **g5**, **g6** and **g7** showed promising in vivo antileishmanial activity (Table [49](#Tab49){ref-type="table"}, Fig. [13](#Fig13){ref-type="fig"}) \[[@CR58]\].Table 49Antileishmanial activity of compounds against amastigotes of *Leishmania donovani* in hamstersCompoundsDose (mg/kg)In vivo inhibition (%)Day-7Day-28**g4**5066--**g5**502263**g6**5064--**g7**5064--

Miscellaneous activities {#Sec10}
------------------------

A new series of strobilurin-pyrimidine derivatives was synthesized by Chai et al. The synthesized compounds were evaluated for their acaricidal activity. Preliminary bioassays demonstrated that compounds, **h1** and **h2** exhibited significant control against *Tetranychus cinnabarinus* (Boisd.) at 0.625 mg/l, and their acaricidal potencies were higher than pyriminostrobin in a green house. Compounds, **h1** and **h2** (Fig. [14](#Fig14){ref-type="fig"}) were chosen as candidates for extensive greenhouse bioassays on larvae and eggs of *T. cinnabarinus.* Both of them showed potency consistent with pyriminostrobin against larvae and weaker potency than pyriminostrobin against eggs, as shown in Table [50](#Tab50){ref-type="table"} \[[@CR59]\].Fig. 14Chemical structures of the most active pyrimidine derivatives (**h1**--**h15**) Table 50Acaricidal activity of **h1** and **h2** against *T. cinnabarinus*Compounds*T. cinnabarinus*(% mortality at given concentration mg/l)10250.625**h1**Larvae1009877Eggs1007025**h2**Larvae100100100Eggs752010PyriminostrobinLarvae10010096Eggs10010020

Amin et al. synthesized a new series of novel coumarin--pyrimidine hybrids and evaluated its vasorelaxant activity against nor-adrenaline-induced spasm on thoracic rat aorta rings and compared to prazocin (reference drug). From the series, compounds, **h3**: (6-(4,6-dimethylpyrimidin-2-ylamino)-2*H*-chromen-2-one) and **h4**: (6-(diethylamino)-5-isocyano-2-(2-oxo-2*H*-chromen-6-ylamino)pyrimidin-4(3*H*)-one) were found to be most prospective vasorelaxant agent with IC~50~ = 0.411 and IC~50~ = 0.421 mM respectively when compared with reference drug prazocin (IC~50~ = 0.487 mM). The chemical structure depicted in Fig. [14](#Fig14){ref-type="fig"} \[[@CR60]\].

Duan et al. designd and synthesized a new series of S(−)-2-(4-chlorophenyl)-*N*-(5,7-di- substituted-2*H*-\[1,2,4\]-thiadiazolo\[2,3-*a*\]pyrimidin-2-ylidene)-3-methylbutanamide derivatives. The synthesized compounds were evaluated for their herbicidal activity against three monocotyledon weeds and two dicotyledon weeds i.e. *Echinochloa crusgallis* L., *Sorghum bicolort*, *Digitaria sanguinalis* (L.) *scop Chenopodium serotinum* (L.) and *Amaranthus retroflexus* L., respectively. Compounds **h5** and **h6** showed the highest inhibitory activity against root and stalk of *Amaranthus retroflexus* L. in higher concentration (1.0 × 10^−4^ µg/ml), while compounds **h7** and **h8** showed good activity against root of *Echinochloa crusgallis* L. and stalk of *Chenopodium serotinum* L., respectively (Table [51](#Tab51){ref-type="table"}, Fig. [14](#Fig14){ref-type="fig"}). The chiral target compounds showed improved herbicidal activity to some extent over their racemic counterparts against a variety of tested weeds, which might be contributed by the introduction of chiral active unit \[[@CR61]\].Table 51The inhibition percentage of the target compounds against various weedsCompoundsConcentration (ppm)*Echinochloa crusgallis* L.*Chenopodium serotinum* L.*Amaranthus retroflexus* L.StalkRootStalkRootStalkRoot**h5**505030505050501008030808595100**h6**5010708080908510030908590100100**h7**5060801010001007010020102030**h8**503070705060501004080100809590

Katiyar et al. developed a new series of trisubstituted pyrimidine derivatives and evaluated its in vitro topoisomerase II inhibitory activity against filarial parasite *Setaria cervi*. Compounds (**h9**--**h15**) have shown 60--80% inhibition at 40 and 20 µg/ml concentrations. Structure activity relationship of most active compounds have given clear indication that amino group and 4-aminophenyl group at position-2 are very crucial in exerting topoisomerase II inhibitory activity against filarial parasite *Setaria cervi* than standard antifilarial drug (DEC) and enzyme topoisomerase II inhibitors (novobiocin, nalidixic acid) (Table [52](#Tab52){ref-type="table"}, Fig. [14](#Fig14){ref-type="fig"}) \[[@CR62]\].Table 52Topoisomerase II inhibitory activity against filarial parasite *Setaria cervi*Compounds% Inhibition at different concentrations40 µg/ml20 µg/ml10 µg/ml5 µg/ml**h9**6060----**h10**6060----**h11**808080--**h12**80808060**h13**80808060**h14**80808025**h15**70707040DEC (antifilarial)4510----Novobiocin (topo II inhibitor)802010--Nalidixic acid (topo II inhibitor)804020--

A new class of 2,4,6-trisubstituted bis-pyrimidines was synthesized by Parveen et al. and screened for its in vitro antiamoebic activity against HM1:IMSS strain of *Entamoeba histolytica* and toxicological studies on PC12-rat pheochoromocytoma cell line.

Bis-pyrimidine having methyl-substituent exhibited higher antiamoebic activity than the reference drug metronidazole (IC~50~ = 1.9 µM). Compound **h16**: 1,3-bis(2-(piperidin-1-yl)-6-(*p*-tolyl)pyrimidin-4-yl)benzene was found most active (IC~50~ = 0.10 µM) and least toxic among all the synthesized compounds (Table [53](#Tab53){ref-type="table"}, Fig. [15](#Fig15){ref-type="fig"}) \[[@CR63]\].Table 53Antiamoebic activity and toxicity profile of compound **h16**CompoundAntiamoebic activityToxicity profile(IC~50~ = µM)SD (±)(IC~50~ = µM)Safety index**h16**0.100.014\> 100\> 1000Metronidazole90.020\> 100\> 52.63*SD* standard deviation Fig. 15Chemical structures of the most active pyrimidine derivatives (**h16**--**h18**)

A new class of pyrido\[2,3-*d*\]pyrimidine derivatives was designed and synthesized by Ibrahim and Ismail. The pyrido\[2,3-*d*\]pyrimidine derivatives were evaluated for their in vitro anti-proliferative activity against A431a, SNU638b, HCT116 and inhibition of CDK2-Cyclin A, CDK4/Cyclin D and EGFR enzyme. In this class, the anti-proliferative and CDK2-Cyclin A inhibitory activity of compounds, **h17** and **h18** (Fig. [15](#Fig15){ref-type="fig"}) was significantly more active than roscovotine (as standard drug) with IC~50~ values of 0.3 and 0.09 µM respectively \[[@CR64]\].

Conclusion {#Sec11}
==========

In conclusion, the biological potentials i.e. antimicrobial, anticancer, antiviral, anti-inflammatory, analgesic, antioxidant and antimalarial of pyrimidine derivatives are summarized. Pyrimidine is the important heterocyclic compound as they are being an essential constituent of cells and large number of marketed drugs. The biological activities of the pyrimidine derivatives indicated the maneuverability and versatility, which offer the medicinal chemist a continued interest in the pyrimidine skeleton in medicinal field.
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